{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.3","upperLimit":"74.4","value":"68.8"},{"groupId":"OG001","lowerLimit":"64.6","upperLimit":"76.1","value":"70.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"description":"Kaplan Meier method will be used to estimate overall survival. Time to event is from enrollment to date of death (by any cause). Participants are censored at last contact or 2 years anniversary of enrollment into this study, whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \\> 100-500/uL following the nadir or the next chemotherapy course begins.\n\nCaspofungin Acetate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Arm I (Caspofungin Acetate)"},{"description":"Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.\n\nFluconazole: Given IV or PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Arm II (Fluconazole)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients (ineligible and inevaluable due to having IFI before IFI monitoring period were excluded)","reportingStatus":"POSTED","timeFrame":"Up to 2 years post enrollment","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}